CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 16 enrolled
Drug / intervention
VAS203 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02992236
NCT02992236Phase 1Completed
CompareCT.gov

Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers

veriNOS operations GmbH·interventional·Posted Dec 14, 2016·Updated Aug 9, 2019

In Brief

A Phase 1 clinical trial evaluating VAS203 and Saline for Renal Function Impairment in Healthy Volunteers. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Analysis of the effect of the NO-Synthase inhibitor VAS203 (6 hours infusion of 10 mg/kg) on renal function and perfusion in 16 healthy subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Function Impairment in Healthy Volunteers
CountriesGermany
CollaboratorsWinicker Norimed GmbH

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 14, 2016
Enrollment StartAug 1, 2015
Primary CompletionMay 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 9.5 years ago

Interventions

VAS203drug

Infusion of NO-Synthase inhibitor VAS203

Salinedrug

Infusion of saline